MitoQ

Phase 2Small molecule

AAntipodean Pharmaceuticals, Inc.

MitoQ is one of 113 small molecule programs targeting Lower Urinary Tract Symptom. It is currently in Phase 2.

Indications

Total Trials

Active Trials

112

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lower Urinary Tract SymptomActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Multiple SclerosisActive, not recruiting

SchizophreniaActive, not recruiting

Lower Urinary Tract SymptomPhase 2

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 1

Active, not recruiting

Multiple SclerosisPhase 1/Phase 2

Active, not recruiting

SchizophreniaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

MitoQ

AAntipodean Pharmaceuticals, Inc.

Phase 2

1 2

Celexa

AbbVie

Preclinical

4 3

Ozempic

Novo Nordisk

Preclinical

1 4

Resotran

Takeda

Preclinical

1 5

Zocor

OOrganon and Co

Preclinical

6 6

Depakote

Ibrance

Luvox

SSolvay Pharmaceuticals

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Recruiting

Schizophrenia

NCT06191965

Clinical

Trials by Indication[1]

Schizophrenia1 trial

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

Recruiting·MMclean Hospital·Phase 2/3·NCT06191965·100 enrolled

Parkinson's Disease1 trial

A Trial of MitoQ for the Treatment of People With Parkinson's Disease

Completed·AAntipodean Pharmaceuticals, Inc.·Phase 2·NCT00329056·128 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)

Terminated·VVirginia Commonwealth University·Phase 1·NCT05605548·4 enrolled

Treatment1 trial

ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

Completed·—·Phase 2·NCT06429059·50 enrolled

Efficacy1 trial

The Efficacy of Oral Mitoquinone (MitoQ) Supplementation for Improving Physiological in Middle-aged and Older Adults

Completed·UUniversity of Colorado, Boulder·N/A·NCT02597023·55 enrolled

2 more indications

Multiple Sclerosis1 trial

MitoQ for Fatigue in Multiple Sclerosis (MS)

Active, not recruiting·VVA Office of Research and Development·Phase 1/2·NCT04267926·45 enrolled

Lower Urinary Tract Symptom1 trial

Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome

Recruiting·IIman Al-Naggar, PhD·Phase 2·NCT06351683·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for MitoQ. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MitoQ compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MitoQ. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Antipodean Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAntipodean Pharmaceuticals, Inc.

MitoQ

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Schizophrenia1 trial

Parkinson's Disease1 trial

Chronic Obstructive Pulmonary Disease1 trial

Treatment1 trial

Efficacy1 trial

Multiple Sclerosis1 trial

Lower Urinary Tract Symptom1 trial

References

Drug Info

Quick Facts

Related News